Consortium seeks SME specialized in peptids as therapeutics or diagnostics for EuroTransBio Project (12th transnat. call)

Research & Development Request
A bioinformatic SME from Germany is searching for SME partners for a project in the EuroTransBio 12th transnat. call on method allowing to use next-generation sequencing and high throughput binding data of combinatorial selection procedures used for the development of new biologics to predict optimized biological lead structures, incl. new algorithms. The partner should perform selections for new biologics, provide enriched libraries for sequencing, and perform functional tests with candidates.
The objective of the project is to develop innovative algorithms based on deep learning (machine learning) techniques to use available sequence and functional data to predict optimized biologics in silico. The basis for this method will be developed by using peptides as a model case but will be extended to more complex proteins like antibodies in a second phase. The final product is a user-friendly software, which allows researchers the in silico optimization of their biologics under development in house.

Users are pharmaceutical or biotech companies as well as academic research groups active in the development of novel biologics (therapeutics or diagnostics).

The company and two other German partners (universities) have the expertise in the development of algorithms and software, deep learning methods, NGS analysis and chip-based high-throughput binding analysis of initial candidates.

The partner SME, which is sought to complement the consortium, should have programs for the development of peptides (pure or enclosed in a scaffold), provide enriched libraries for NGS, and perform secondary functional tests of selected peptides in its own systems. The partner would greatly benefit by enhancing its own research programs and having access to our bioinformatic know-how.

Details for EuroTransBio 12th transnational call that applies here:

The partner SME should be located in Austria, Flanders (Belgium), Finland, France (Alsace, Champagne-Ardenne and Lorraine), Italy, or Russia due to the restrictions of the current EuroTransBio 12th transnational call.

The deadline for EOIs is 9th of December 2016 (although earlier EOIs are highly encouraged because of the winter holidays).

The deadline for the submission of the proposal is January 31st, 2017.

Anticipated start of the project is in the middle of 2017.
The problem: Next-generation sequencing (NGS) analysis is a powerful method to identify even rare ligands in in vitro selection experiments for novel biologics amongst millions of candidates. However, these data just represent a small fraction of all possible lead molecules. Thus, initial ligands have to be optimized for optimal function but also for cost-effective production in a laborious and expensive lead optimization process. Frequently, not the best biological product is found. The solution which will be developed in this project is to combine for the first time the existing sequencing data with functional data in a high-throughput fashion with the aim to predict optimized lead candidates in silico. This innovative method (novel algorithms) will be integrated in an intuitive, user-friendly software, which enables non-bioinformaticians an easy access to take advantage of big data to develop better products.
Comments Regarding IPR Status: Main product of the company is software, which cannot be protected by patents. Software itself is protected by copyrights, specific algorithms as secret know how.


No Man flag

No Support in this time. please use Contact us form!